Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.83 |
| ▸ | MEN1 | O00255 | 1/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.77 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.77 |
| ▸ | MBNL1 | Q9NR56 | 1/20 | 0.76 |
| ▸ | GSR | P00390 | 7/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | PHLPP2 | Q6ZVD8 | 2/20 | 0.61 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | PRNP | P04156 | 1/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.58 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.58 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.58 |
| ▸ | HTR1A | P08908 | 1/20 | 0.58 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.58 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.58 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.58 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7875793 | 1.00 | ADORA2A (0.83) | ADORA2AMEN1KMT2ATDP1MBNL1 | |
| SCHEMBL7869225 | 0.96 | MBNL1 (0.81) | ADORA2AMEN1KMT2ATDP1MBNL1 | |
| SCHEMBL7880398 | 0.96 | MEN1 (0.79) | ADORA2AMEN1KMT2ATDP1MBNL1 | |
| SCHEMBL20087027 | 0.95 | MBNL1 (0.80) | ADORA2AMEN1KMT2ATDP1MBNL1 | |
| SCHEMBL20087077 | 0.95 | MBNL1 (0.80) | ADORA2AMEN1KMT2ATDP1MBNL1 | |
| SCHEMBL20087053 | 0.95 | MBNL1 (0.80) | ADORA2AMEN1KMT2ATDP1MBNL1 | |
| SCHEMBL23795497 | 0.94 | MBNL1 (0.75) | ADORA2AMEN1KMT2ATDP1MBNL1 | |
| SCHEMBL7874381 | 0.94 | ADORA2A (0.78) | ADORA2AMEN1KMT2ATDP1MBNL1 | |
| SCHEMBL22420449 | 0.94 | ADORA2A (0.74) | ADORA2AMEN1KMT2ATDP1MBNL1 | |
| SCHEMBL23904131 | 0.93 | MBNL1 (0.77) | ADORA2AMEN1KMT2ATDP1MBNL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4168054-A1 | CONJUGATED AND LABELLED APELIN, PREPARATION AND USES THEREOF | Universite d'Aix Marseille (FR) | 2023-04-26 | — | — | EP | claimed |
| EP-4709718-A1 | 6-SUBSTITUTED-3-PHENYL-ISOINDOLIN-1-ONES AS CBL-B INHIBITORS SELECTIVE OVER C-CBL | Genentech Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| WO-2025104679-A1 | PROCESSES FOR MAKING INTERMEDIATES FOR ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2025-05-22 | — | — | WO | disclosed |
| EP-4508109-A1 | COMPOSITION, URETHANE PREPOLYMER, AND RELATED METHODS AND USES | Dow Silicones Corporation (US) | 2025-02-19 | — | — | EP | disclosed |
| WO-2024189607-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT | DIDENKO KIRILL (MX) | 2024-09-19 | — | — | WO | disclosed |
| EP-4413009-A1 | PREPARATION OF AMINO-FUNCTIONAL ORGANOSILICON COMPOUNDS | Dow Global Technologies LLC (US) | 2024-08-14 | — | — | EP | disclosed |
| EP-4413010-A1 | PREPARATION OF IMINE-FUNCTIONAL ORGANOSILICON COMPOUNDS AND PRIMARY AMINO-FUNCTIONAL ORGANOSILICON COMPOUNDS | Dow Global Technologies LLC (US) | 2024-08-14 | — | — | EP | disclosed |
| CN-111065744-B | Method for producing chiral amines | 威妥有限公司 | 2024-05-03 | — | — | CN | disclosed |
| EP-4323358-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING CANCER | Hotspot Therapeutics, Inc. (US) | 2024-02-21 | — | — | EP | disclosed |
| WO-2023200684-A1 | COMPOSITION, URETHANE PREPOLYMER, AND RELATED METHODS AND USES | DOW SILICONES CORPORATION (US) | 2023-10-19 | — | — | WO | disclosed |
| EP-4180424-A1 | SUBSTITUTED PYRAZOLES AS HUMAN PLASMA KALLIKREIN INHIBITORS | BioCryst Pharmaceuticals, Inc. (US) | 2023-05-17 | — | — | EP | disclosed |
| CN-116134068-A | Polymerization process | 牛津大学科技创新有限公司 | 2023-05-16 | — | — | CN | disclosed |
| WO-2023060153-A1 | PREPARATION OF AMINO-FUNCTIONAL ORGANOSILICON COMPOUNDS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2023-04-13 | — | — | WO | disclosed |
| WO-2023060154-A1 | PREPARATION OF IMINE-FUNCTIONAL ORGANOSILICON COMPOUNDS AND PRIMARY AMINO-FUNCTIONAL ORGANOSILICON COMPOUNDS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2023-04-13 | — | — | WO | disclosed |
| EP-4153591-A1 | METHODS OF MAKING WEE1 INHIBITOR COMPOUNDS | Recurium IP Holdings, LLC (US) | 2023-03-29 | — | — | EP | disclosed |
| WO-2022256525-A1 | COBALT CATALYSTS CONTAINING \"SMART\"OR\"TASK SPECIFIC\"ANIONS | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2022-12-08 | — | — | WO | disclosed |
| CN-115260203-A | Quinoxalino-phenazine luminescent material and application thereof | 浙江工业大学 | 2022-11-01 | — | — | CN | disclosed |
| WO-2022221704-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING CANCER | HOTSPOT THERAPEUTICS, INC. (US) | 2022-10-20 | — | — | WO | disclosed |
| US-20220041634-A1 | Three-Dimensional Organic Sandwich Chirality and Its Synthetic Assembly | TEXAS TECH UNIVERSITY SYSTEM | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220041634-A1 | Three-Dimensional Organic Sandwich Chirality and Its Synthetic Assembly | WNT3, CTNNB1, ORC3 | ADORA2A 4500/4885MEN1 1644/4885KMT2A 1359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.